Inactive Instrument
BELM PHAR Stock Nasdaq
Stocks
Biotechnology & Medical Research
OTC Markets Traded| 1 day | -1.76% |
| Manager | Title | Age | Since |
|---|---|---|---|
Dave Maggio
CEO | Chief Executive Officer | 66 | 2024-02-22 |
Richard Fair
CEO | Chief Executive Officer | 57 | 2017-01-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Richard Fair
BRD | Director/Board Member | 57 | - |
Judith Kilmovsky
BRD | Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.76% | -12.95% | - | - | 822K | |
| +2.35% | +2.74% | +33.41% | +79.20% | 56.54B | |
| -0.21% | -7.38% | +25.34% | +63.02% | 53.6B | |
| -2.44% | +1.40% | -15.74% | -16.80% | 22.91B | |
| -2.85% | -7.78% | -8.09% | +346.36% | 21.37B | |
| +2.49% | -0.92% | +20.31% | -12.15% | 20.27B | |
| +0.79% | -1.06% | +29.29% | -33.32% | 17.56B | |
| +0.58% | -5.88% | +16.30% | +540.37% | 14.75B | |
| -5.25% | -4.23% | +46.41% | +169.05% | 13.33B | |
| +3.41% | -6.61% | +163.08% | +280.43% | 13.53B | |
| Average | -0.29% | -3.79% | +34.48% | +157.35% | 25.98B | |
| Weighted average by Cap. | +0.23% | -2.96% | +28.67% | +119.98% |
| 2021 | 2022 | |
|---|---|---|
| Net sales | 6.2M 5.39M 5.02M 4.61M 8.7M 592M 8.83M 59.13M 23.21M 295M 23.28M 22.77M 988M | 1.5M 1.3M 1.21M 1.11M 2.1M 143M 2.14M 14.31M 5.61M 71.29M 5.63M 5.51M 239M |
| Net income | -9.7M -8.44M -7.85M -7.21M -13.61M -926M -13.83M -92.56M -36.33M -461M -36.45M -35.65M -1.55B | -24.97M -21.71M -20.21M -18.55M -35.03M -2.38B -35.58M -238M -93.48M -1.19B -93.79M -91.73M -3.98B |
| Net Debt | - | - |
Employees
-
